Travere Therapeutics, Inc. TVTX License and collaboration revenue — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s license and collaboration revenue — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s license and collaboration revenue — total revenue?
- Travere Therapeutics, Inc. (TVTX) reported license and collaboration revenue — total revenue of $2.71M in Q1 2026.
- How has Travere Therapeutics, Inc.'s license and collaboration revenue — total revenue changed year-over-year?
- Travere Therapeutics, Inc.'s license and collaboration revenue — total revenue decreased by 54.1% year-over-year, from $5.9M to $2.71M.
- What is the long-term trend for Travere Therapeutics, Inc.'s license and collaboration revenue — total revenue?
- Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s license and collaboration revenue — total revenue has grown at a -37.0% compound annual growth rate (CAGR), from $26.04M to $6.51M.
- What does license and collaboration revenue — total revenue mean?
- This metric represents the total gross revenue generated from licensing intellectual property and strategic collaboration agreements with third-party partners. It reflects the company's ability to monetize its research and development pipeline through partnerships rather than direct commercial sales. This serves as a key indicator of the commercial viability and market interest in the company's proprietary therapeutic candidates.